Reuters logo
Proteon Therapeutics kidney drug fails key study
December 13, 2016 / 12:17 PM / a year ago

Proteon Therapeutics kidney drug fails key study

Dec 13 (Reuters) - Proteon Therapeutics Inc said its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study.

The drug, vonapanitase, was being tested against a placebo in certain patients on or expecting to undergo dialysis.

The company’s shares were halted in premarket trading. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D‘Silva)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below